Rimonabant acomplia, weight loss pill.Rimonabant acomplia, weight loss pill.Information about rimonabant, also known as acomplia or zimulti. Articles
Accepted Discover rimonabant Acomplia
2007-08-27 18:42:00 Diet drug rimonabant (Acomplia / Zimulti) faces its moment of truth in the United States during the week ahead. On Tuesday, June 12th, the FDA staff will for the first time reveal its views on the long-delayed diet drug. The following day, June 13th, the agency?s Endocrinologic and Metabolic Drug Advisory Committee, a panel of outside experts, ... More About: About , Rimonabant , Discover , Disc
Blockade by the Cannabinoid CB1 Receptor Antagonist, Rimonabant (SR141716),
2007-08-25 19:22:00 It has been shown previously that the selective cannabinoid CB1 receptor antagonist, rimonabant (SR141716), reduced the intake of palatable food as well as the self-administration of several drugs of abuse, suggesting that endocannabinoid systems play a role in brain reward function. The present study investigated whether a cannabinoid step was involved in food-seeking behavior induced ... More About: About , Rimonabant , Mona
The Medication Rimonabant (Acomplia) produce modest yet sustained weight lo
2007-08-25 19:21:00 Approximately two-thirds of U.S. adults are overweight or obese, which greatly increases the risk of developing diabetes mellitus and cardiovascular disease and death from related causes. Researchers believe that besides weight loss, obesity management should target improvement in certain cardiometabolic risk factors, which include abnormal cholesterol and glucose (blood sugar) levels and excess weight around ... More About: Weight , About , Modest , Medication , Acomplia
Acomplia can induce penile erection in male rats: Involvement of paraventri
2007-08-25 19:21:00 The cannabinoid CB1 receptor antagonist SR141716A (0.5, 1 and 2mug) induces penile erection when injected into the paraventricular nucleus of male rats. The pro-erectile effect of SR 141716A occurs concomitantly with an increase in the concentration of NO(2)(-) and NO(3)(-) in the paraventricular dialysate obtained by means of intracerebral microdialysis. Both penile erection and NO(2)(-) increase ... More About: About , Male , Acomplia , Raven , Erection
Weight Loss and Rimonabant
2007-08-25 19:20:00 Weight Loss and Rimonabant Belgian researchers writing in the Lancet said people taking rimonabant lost an average of 8.6 kilograms (18.9 pounds) in a year. They also lost an average of 8.5 centimetres (over three inches) from their waists. UK experts commented that rimonabant might help people lose weight - but could not replace eating healthily. In ... More About: Weight Loss , Weight , Eight
Acomplia: Easiest way to quit habitual smoking with Acomplia
2007-08-25 19:19:00 Acomplia is a novel prescription drug with two in one benefits. It checks the obesity and controls the temptation to smoke. This wonderful drug suppresses the hunger center in brain and thus lowers your appetite. You will not feel hungry when you take this drug. Discount Acomplia controls blood cholesterol by decreasing bad cholesterol LDL ... More About: Quit Smoking , Smoking , Quit , Acomplia , Abit
If You Want Acomplia (Rimonabant), You Won?t Find It Anywhere as Zimulti
2007-08-25 19:19:00 In the wake of the diet drug rimonabant (Acomplia / Zimulti) debacle on June 13th, there is no need for millions of Americans eager to try Acomplia to look for it under the new name Zimulti. Barring a miracle, rimonabant will not be approved by the FDA for sale in the United States ? where developer ... More About: Find , About , Rimonabant , Mona
Acomplia: Your Quest for Obesity check ends with Acomplia
2007-08-25 19:18:00 Acomplia is a French drug designed to quit the smoking and check obesity. It suppresses the appetite by blocking hunger signals to brain.Acomplia affects endocannabinoid system.Acomplia targets newly discovered hunger center Cannabinoid receptors in the brain thus controlling the hunger. It is a wonderful drug for treatment of obesity in a differentmanner. According to World ... More About: Obesity , Check , Quest , Ends , Acomplia
Study: Diet Drug Rimonabant May Reduce Obesity-Related Liver Damage
2007-08-25 19:17:00 A new animal study on rimonabant (Acomplia / Zimulti) has identified yet one more possible health benefit for this controversial diet drug: it appears to reduce obesity-related liver damage that can lead to cirhossis of the liver. A team of researchers led by Mohammed Bensaid of Sanofi-Aventis, the company that has developed rimonabant, reported on these ... More About: Diet , Study , Obesity , About , Reduce
Sanofi Pulls U.S. Application for Approval of Diet Drug Acomplia (Rimonaban
2007-08-25 19:16:00 Sanofi-Aventis on June 29th temporarily ended its effort to get diet drug rimonabant (Acomplia / Zimulti) approved for sale in the United States, withdrawing its application rather than await next month?s near-certain rejection by the U.S. Food and Drug Administration. The action came less than two weeks after the FDA?s expert advisory committee unanimously recommended that ... More About: Diet , About , Sanofi , Application
More Rimonabant Trial Results
2007-08-25 19:16:00 When two year results of the RIO-North America (Rimonabant In Obesity) trial were presented at the American Heart Association (AHA) scientific meeting in New Orleans in November, researchers said additional results from studies underway could be expected by the end of the year. But seven weeks have passed with no news on when additional data from ... More About: Results , About , Trial , Result
What is Rimonabant?
2007-08-24 18:21:00 Rimonabant (also known as SR141716, Acomplia, Riobant, Slimona, Rimoslim, and Zimulti) is an anorectic anti-obesity drug. It is a CB1 cannabinoid receptor antagonist. Its main avenue of effect is reduction in appetite. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. In Europe, it is indicated for use ... More About: Rimonabant , Mona
Diet Pills Acomplia (Rimonabant) and Alli (Low-Dose Xenical) Remain Stalled
2007-08-24 18:20:00 A year ago at this time, millions of overweight and obese Americans were excitedly awaiting both a new prescription weight-loss drug, rimonabant (Acomplia / Zimulti), and the first over-the-counter diet drug, Alli (low-dose Xenical ), which were expected to be on the U.S. market by summer. But twelve disappointing months later, FDA approval of Acomplia and Alli ... More About: Diet , About
Decisions Drawing Near on Approval of Sale of Acomplia
2007-08-24 18:20:00 The moment of truth for the new diet drug Acomplia (rimonabant), currently awaiting decisions on regulatory approval both in the United States and Europe, would appear to be drawing near. Sanofi-Aventis, which developed the drug, submitted Phase III clinical trial results to both the U.S. Food and Drug Administration and European regulators early last summer, expressing ... More About: Drawing , Sale , About , Decisions
Long-Term Data Needed on Diet Drugs to Prove Benefits Outweigh Risks
2007-08-24 18:19:00 Diet drugs like Acomplia (rimonabant), Xenical and Meridia that patients may need to take for years require more study to see if they also help people live longer before doctors can be sure the benefits are greater than the risks, according to Canadian researchers writing in The Lancet. While Acomplia, which is not yet approved in ... More About: Drugs , Diet , Data , About , Long
Commentary: Mythology of Acomplia Plays to Magic Pill Approach to Health
2007-08-24 18:19:00 Mike Adams, a holistic nutritionist who has authored a number of books on nutrition, wellness, food toxicology and the causes of disease and health, has written the following commentary on the weight-loss drug Acomplia. The views are his own, and are reported because of the widespread interest in this subject. A new weight loss drug, Acomplia, ... More About: Mythology , Health , Commentary , Magic , About
Commentary: Mythology of Acomplia Plays to Magic Pill Approach to Health co
2007-08-24 18:18:00 The seduction of Acomplia is that it takes over our responsibilities. It allows us to shift control of our lives from our own conscious intentions to a prescription drug handed out to us by doctors. It is in this very mythology that the danger to Americans hides. Not in the drug itself ? it is ... More About: Mythology , Health , Commentary , Magic , About
Commentary: Mythology of Acomplia Plays to Magic Pill Approach to Health pa
2007-08-24 18:16:00 Now certainly, genes can be a factor. There are some people who are born with greater ability to store food as body fat. There are other people born with stronger hearts. Some people didn?t get good nutrition when they were infants, because their pregnant mothers didn?t know about good nutrition and didn?t feed them well, ... More About: Mythology , Health , Commentary , Magic , About
Report Says Acomplia Still Must Overcome ?Skepticism About Its Side Effects
2007-08-24 18:12:00 An article set for publication in the respected journal, Nature Medicine, says that while Acomplia (rimonabant) may turn out to be the ?Prozac of obesity,? it still faces the challenge of overcoming ?skepticism about its side effects.? The article notes the troubled past of obesity drugs, ranging from misuse of amphetamines to the ?fen-phen debacle of ... More About: Skepticism , Report , About , Side , Overcome
Expert Says Overactive Endocannabinoid System May Be Key Factor in Obesity
2007-08-24 18:11:00 Dr. Louis J. Aronne, a leading authority on obesity and long a strong supporter of diet drug rimonabant (Acomplia / Zimulti), says ?what many people have traditionally viewed as a lack of willpower [to stop eating] could actually have a biochemical basis? found in the endocannabinoid (EC) system. ?It?s not just a matter of lack of ... More About: System , Obesity , About , Expert , Factor
Report: Regulators Will Be Wary in Weighing Up Acomplia
2007-08-24 18:10:00 The Guardian, in the following story published on January 10, 2005, says that while Sanofi is confident it has a winner in the new anti-obesity drug Acomplia , it can expect close scrutiny during the approval process of the side effects. Want to lose weight, stop smoking and cut down on your alcohol consumption? An easy way ... More About: Report , About , Weigh
Report Says Acomplia Still Must Overcome ?Skepticism About Its Side Effects
2007-08-23 17:45:00 An article set for publication in the respected journal, Nature Medicine, says that while Acomplia (rimonabant) may turn out to be the ?Prozac of obesity,? it still faces the challenge of overcoming ?skepticism about its side effects.? The article notes the troubled past of obesity drugs, ranging from misuse of amphetamines to the ?fen-phen debacle of ... More About: Skepticism , Report , About , Side , Overcome
Expert Says Overactive Endocannabinoid System May Be Key Factor in Obesity
2007-08-23 17:43:00 Dr. Louis J. Aronne, a leading authority on obesity and long a strong supporter of diet drug rimonabant (Acomplia / Zimulti), says ?what many people have traditionally viewed as a lack of willpower [to stop eating] could actually have a biochemical basis? found in the endocannabinoid (EC) system. ?It?s not just a matter of lack of ... More About: System , Obesity , About , Expert , Factor
Report: Regulators Will Be Wary in Weighing Up Acomplia
2007-08-23 17:40:00 The Guardian, in the following story published on January 10, 2005, says that while Sanofi is confident it has a winner in the new anti-obesity drug Acomplia , it can expect close scrutiny during the approval process of the side effects. Want to lose weight, stop smoking and cut down on your alcohol consumption? An easy way ... More About: Report , About , Weigh
Two New Clinical Trials of Acomplia Now Underway
2007-08-23 17:38:00 Two new Phase III clinical trials of Acomplia ? one of them by far the largest yet ? are now underway as part of an effort by developer Sanofi-Aventis to assess the potential role of the drug in reducing the risk of heart attacks or strokes in patients with abdominal obesity and other risk factors. The ... More About: About , Clinical Trials , Trials , Under
Diet Drug Acomplia Rejected for Coverage by German State Health Insurance
2007-08-23 17:34:00 The diet drug Acomplia (rimonabant) will not be reimbursed by health insurance in German y, the European Union?s largest market, according to a decision by the German Ministry of Health published Jan. 11th in the official journal of the government. The decision to classify Acomplia as a ?lifestyle treatment? comes as a serious blow to manufacturer Sanofi-Aventis, ... More About: Insurance , Diet , Health Insurance
Report: Acomplia Is ?Product to Watch? for 2005
2007-08-23 17:25:00 The magazine Med Ad News, in an article on ?future blockbuster drugs,? has named Acomplia its ?Product to Watch for 2005? and said experts feel it has the potential to become the pharmaceutical industry?s once-in-a-decade blockbuster. Below are excerpts from its report: Acomplia?s potential resides in its promising therapeutic profile in two vast and highly underserved ... More About: Report , About
Report: Acomplia Could Be Approved by FDA ?As Early as Next Month?
2007-08-23 17:24:00 Reuters, in a story about the anti-obesity drug Acomplia (rimonabant), reported on January 15th that the medicine could be approved by the U.S. Food and Drug Administration ?as early as next month.? Reuters provided no source for its optimistic projection, and a number of FDA observers believe a decision on approving Acomplia for sale in the ... More About: Report , About , Early , Earl
Diet Drug Rimonabant (Acomplia / Zimulti) Not Yet Available in Mexico
2007-08-23 17:22:00 While diet drug Acomplia (rimonabant) has been approved for sale in Mexico since Nov. 9th, the diet pill does not seem to be generally available yet in Mexican pharmacies. A survey of some of Mexico?s largest pharmacies on Jan. 16-17 turned up no sign of the highly anticipated diet drug, nor were pharmacies able to shed ... More About: Diet , About , Drug
Article Urges FDA to Limit Acomplia to ?Those Who Need the Drug to Survive?
More articles from this author:2007-08-23 17:20:00 A Virginia Tech student newspaper has gotten quite a bit of attention in the past two days with an article on Acomplia suggesting that while a pill that combats obesity and potentially decreases the risk of heart complications sounds like a great idea, it ?could end up creating more problems than it solves.? In the article, ... More About: Article , About , Survive , Drug 1, 2, 3, 4, 5, 6 |
|
 |
|
 |
